| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.JURO.2015.02.2918 |
| P8608 | Fatcat ID | release_h4hr2dn23jg4hadmbdnmhqbee4 |
| P932 | PMC publication ID | 6371809 |
| P698 | PubMed publication ID | 25748177 |
| P2093 | author name string | Gang Li | |
| Song Wang | |||
| Lin Du | |||
| Hanwei Zhang | |||
| Arnold I Chin | |||
| Elizabeth Peek | |||
| David R Li | |||
| P2860 | cites work | Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells | Q24657020 |
| Cancer statistics, 2013 | Q27860762 | ||
| Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study | Q28139358 | ||
| Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis | Q28277806 | ||
| Comprehensive molecular characterization of urothelial bladder carcinoma | Q28306864 | ||
| MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer | Q29617772 | ||
| Vorinostat in solid and hematologic malignancies | Q33385544 | ||
| Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy | Q33572016 | ||
| Histone deacetylase (HDAC) 1 and 2 are essential for accurate cell division and the pluripotency of embryonic stem cells | Q33919809 | ||
| Cisplatin-induced apoptosis inhibits autophagy, which acts as a pro-survival mechanism in human melanoma cells | Q34600254 | ||
| Inhibitory effect of valproic acid on bladder cancer in combination with chemotherapeutic agents in vitro and in vivo | Q35030146 | ||
| Expression of histone deacetylases 1, 2 and 3 in urothelial bladder cancer | Q35119480 | ||
| Three differentiation states risk-stratify bladder cancer into distinct subtypes | Q35750975 | ||
| The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo | Q36178061 | ||
| HDAC family: What are the cancer relevant targets? | Q37281991 | ||
| Molecular mechanisms of cisplatin resistance in bladder cancer. | Q37982453 | ||
| Cancer stem-like cells contribute to cisplatin resistance and progression in bladder cancer | Q39395076 | ||
| HDAC inhibition delays cell cycle progression of human bladder cancer cells in vitro | Q39493944 | ||
| Experimental study on inhibitory effects of histone deacetylase inhibitor MS-275 and TSA on bladder cancer cells | Q39889318 | ||
| Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer | Q40236236 | ||
| Selective activity of the histone deacetylase inhibitor AR-42 against leukemia stem cells: a novel potential strategy in acute myelogenous leukemia | Q41769694 | ||
| A Phase II Clinical Trial of Oral Valproic Acid in Patients with Castration-Resistant Prostate Cancers Using an Intensive Biomarker Sampling Strategy | Q41863259 | ||
| HDACs link the DNA damage response, processing of double-strand breaks and autophagy | Q41979339 | ||
| Stromal modulation of bladder cancer-initiating cells in a subcutaneous tumor model. | Q42379859 | ||
| Inhibition of bladder tumour growth by histone deacetylase inhibitor | Q43291800 | ||
| Romidepsin for cutaneous T-cell lymphoma | Q83996070 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cisplatin | Q412415 |
| P304 | page(s) | 547-555 | |
| P577 | publication date | 2015-03-03 | |
| P1433 | published in | Journal of Urology | Q15709979 |
| P1476 | title | Synergy of Histone-Deacetylase Inhibitor AR-42 with Cisplatin in Bladder Cancer | |
| P478 | volume | 194 |
| Q47584543 | A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas |
| Q92460583 | AR-42: A Pan-HDAC Inhibitor with Antitumor and Antiangiogenic Activities in Esophageal Squamous Cell Carcinoma |
| Q57452829 | CD24 regulates cancer stem cell (CSC)-like traits and a panel of CSC-related molecules serves as a non-invasive urinary biomarker for the detection of bladder cancer |
| Q64121548 | Histone Deacetylase Inhibitor, Trichostatin A, Synergistically Enhances Paclitaxel-Induced Cytotoxicity in Urothelial Carcinoma Cells by Suppressing the ERK Pathway |
| Q90221601 | Histone deacetylase inhibitor AR-42 inhibits breast cancer cell growth and demonstrates a synergistic effect in combination with 5-FU |
| Q38572855 | Impact of Histone Deacetylase Inhibitors on microRNA Expression and Cancer Therapy: A Review |
| Q28076041 | Molecular targets in urothelial cancer: detection, treatment, and animal models of bladder cancer |
| Q40084337 | Novel histone deacetylase inhibitor AR-42 exhibits antitumor activity in pancreatic cancer cells by affecting multiple biochemical pathways |
| Q57028508 | Trichostatin A, a histone deacetylase inhibitor, induces synergistic cytotoxicity with chemotherapy via suppression of Raf/MEK/ERK pathway in urothelial carcinoma |
Search more.